drugset / Trial / NCT01334944

Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen

NCT01334944

Phase 4 Completed 150 enrolled Cumberland Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to determine the safety of a single dose of intravenous ibuprofen administered over 5-10 minutes for the treatment of fever or pain in the hospital setting.

Timeline

Start
2011-06
Primary completion
2012-09
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibuprofen Small molecule 400 mg Intravenous
Subject Ibuprofen Small molecule 800 mg Intravenous

Indications

No indication recorded.